Kurdo Barwari
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Kurdo Barwari has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
M. Pilar Laguna
Department of Urology, AMC University Hospital, University of Amsterdam, Amsterdam, The Netherlands
4 shared publications- Maria Pilar Laguna
AMC University Hospital
4 shared publications Hessel Wijkstra
Department of Urology, AMC University Hospital, University of Amsterdam, Amsterdam, The Netherlands
3 shared publicationsDaniel M. de Bruin
Departments of Urology
2 shared publications- Dirk J. Faber
University of Amsterdam, Academic Medical Center, Department of Biomedical Engineering and Physics
2 shared publications J J De La Rosette
2 shared publications
Latest Publications
- 1 April 2014
- Published by Elsevier in European Urology Supplements
- Vol. 13 (1) , e97
97 Intermediate term oncologic outcomes of renal cryoablation: An international multi-institution analysis
- 1 April 2014
- Published by Elsevier in European Urology Supplements
- Vol. 13 (1) , e97
97 Intermediate term oncologic outcomes of renal cryoablation: An international multi-institution analysis
- 1 April 2013
- Published by SAGE Publications in Journal of Endourology
- Vol. 27 (4) , 402-407
Contrast-Enhanced Ultrasound for the Evaluation of the Cryolesion After Laparoscopic Renal Cryoablation: An Initial Report
Purpose: Stringent radiological follow-up is essential after renal tumor ablation. Drawbacks of postablation follow-up by contrast-enhanced computed tomography (CECT) are the associated ionizing radiation and nephrotoxic contrast agent. Contrast-enhanced ultrasound (CEUS) has shown potential to demonstrate microvasculature without using either ionizing radiation or toxic contrast agent. We assessed the concordance of enhancement patterns of CEUS and CECT/MRI in cryolesion assessment after laparoscopic renal cryoablation (LCA). Methods: From 01/2006 to 01/2009, a CEUS was performed before and after LCA (3 and 12 months) in addition to regular CECT/MRI. Using an enhancement score (0=no enhancement, 1=rim enhancement, 2=diffuse enhancement, 3=localized enhancement, 4=no enhancement defect), the cryolesion was assessed by both modalities, and concordance of enhancement score was assessed. Results: In total, 45 tumors were included (29 biopsy proven renal cell carcinoma (RCC), mean size 2.66 cm). One cryoablation failed, resulting in a nonenhancing cryolesion apart from the persisting renal tumor. There were no postablation recurrences during the study period. Pre-LCA: Both modalities were available in 26 cases. In 20 out of 26, there was concordance of enhancement score (77%, all cases score 3 or 4). Three months: Both modalities were available in 32 cases. Enhancement score corresponded in 23 out of 32 cases (72%). Seven cases showed enhancement on CECT/MRI (“1” in six cases, “4” in one case) with enhancement score “0”on CEUS. Two cases showed enhancement on CEUS without enhancement on CECT/MRI (specificity 92%, negative predictive value [NPV] 77%). Except one case, all enhancement resolved on subsequent imaging. Twelve months: Both modalities were available in 21 tumors. Enhancement score corresponded in 19 out of 21 cases (91%). Two cases showed enhancement on CEUS without enhancement on CECT/MRI (specificity 90%, NPV 100%). Conclusion: This pilot study shows that CEUS is a safe imaging technique with high concordance of enhancement score between CEUS and CECT/MRI. While cross-sectional imaging seems sensible to demonstrate successful ablation at first follow-up, CEUS might be used to diminish the burden of contrast-enhanced cross-sectional imaging in the long-term follow-up.
- 1 April 2013
- Published by SAGE Publications in Journal of Endourology
- Vol. 27 (4) , 402-407
Contrast-Enhanced Ultrasound for the Evaluation of the Cryolesion After Laparoscopic Renal Cryoablation: An Initial Report
Purpose: Stringent radiological follow-up is essential after renal tumor ablation. Drawbacks of postablation follow-up by contrast-enhanced computed tomography (CECT) are the associated ionizing radiation and nephrotoxic contrast agent. Contrast-enhanced ultrasound (CEUS) has shown potential to demonstrate microvasculature without using either ionizing radiation or toxic contrast agent. We assessed the concordance of enhancement patterns of CEUS and CECT/MRI in cryolesion assessment after laparoscopic renal cryoablation (LCA). Methods: From 01/2006 to 01/2009, a CEUS was performed before and after LCA (3 and 12 months) in addition to regular CECT/MRI. Using an enhancement score (0=no enhancement, 1=rim enhancement, 2=diffuse enhancement, 3=localized enhancement, 4=no enhancement defect), the cryolesion was assessed by both modalities, and concordance of enhancement score was assessed. Results: In total, 45 tumors were included (29 biopsy proven renal cell carcinoma (RCC), mean size 2.66 cm). One cryoablation failed, resulting in a nonenhancing cryolesion apart from the persisting renal tumor. There were no postablation recurrences during the study period. Pre-LCA: Both modalities were available in 26 cases. In 20 out of 26, there was concordance of enhancement score (77%, all cases score 3 or 4). Three months: Both modalities were available in 32 cases. Enhancement score corresponded in 23 out of 32 cases (72%). Seven cases showed enhancement on CECT/MRI (“1” in six cases, “4” in one case) with enhancement score “0”on CEUS. Two cases showed enhancement on CEUS without enhancement on CECT/MRI (specificity 92%, negative predictive value [NPV] 77%). Except one case, all enhancement resolved on subsequent imaging. Twelve months: Both modalities were available in 21 tumors. Enhancement score corresponded in 19 out of 21 cases (91%). Two cases showed enhancement on CEUS without enhancement on CECT/MRI (specificity 90%, NPV 100%). Conclusion: This pilot study shows that CEUS is a safe imaging technique with high concordance of enhancement score between CEUS and CECT/MRI. While cross-sectional imaging seems sensible to demonstrate successful ablation at first follow-up, CEUS might be used to diminish the burden of contrast-enhanced cross-sectional imaging in the long-term follow-up.
- 15 February 2013
- Vol. 66 (1) , 41-53
Laparoscopic cryotherapy for small renal masses: Current State.
To provide an up-to-date review of the available literature on laparoscopic cryotherapy for small renal masses (SRMs) including technique description, indications and outcomes. A systematic literature search was conducted in March 2012, using MEDLINE and EMBASE via Ovid databases, to identify studies on laparoscopic cryotherapy for SRMs published during the last 10 years. Only English-language and human-based full manuscripts reporting case series studies with >20 participants, patient characteristics, efficacy and safety data were included. No randomised controlled trials (RCTs)were identified. In total, 27 full reports addressing laparoscopic cryoablation (LCA) for SRMs were selected. The number of patients per study ranged from 20 to 144. Mean age of treated patients across the series ranged from 62 to 73 years. Mean size of renal tumors ranged from 2.7 to 4 cm, being in most cases <3 cm. The number of cryoprobes used for cryoablation ranged from 1 to 6, and only 10 series described the use of 17-gauge (1.47 mm) third-generation needles. Overall, more than 55% of all ablated lesions were pathologically confirmed RCC. Mean follow-up ranged from 9 to 93 months. Only 7 series presented a long-term follow-up of more than 36 months. Most studies were limited by a relatively short follow-up. At least four urologic groups reported intermediate- and long-term outcomes. Persistence rates ranged from 0% to 17% and recurrence rates ranged from 0% to 14%. Overall complication rates ranged from 0% to 40%. Retrospective observational data and a few prospective series on LCA of SRMs show acceptable oncological 3- to 5-year outcomes with a low recurrence rate. It has proven to be a safe procedure with an overall low complication rate. It is mainly indicated for SRMs in elderly patients affected by co-morbidity and high surgical risk bearing tumours in the anterior valve of the kidney or in contact with the ureter or neighbouring organs.
- 15 February 2013
- Vol. 66 (1) , 41-53
Laparoscopic cryotherapy for small renal masses: Current State.
To provide an up-to-date review of the available literature on laparoscopic cryotherapy for small renal masses (SRMs) including technique description, indications and outcomes. A systematic literature search was conducted in March 2012, using MEDLINE and EMBASE via Ovid databases, to identify studies on laparoscopic cryotherapy for SRMs published during the last 10 years. Only English-language and human-based full manuscripts reporting case series studies with >20 participants, patient characteristics, efficacy and safety data were included. No randomised controlled trials (RCTs)were identified. In total, 27 full reports addressing laparoscopic cryoablation (LCA) for SRMs were selected. The number of patients per study ranged from 20 to 144. Mean age of treated patients across the series ranged from 62 to 73 years. Mean size of renal tumors ranged from 2.7 to 4 cm, being in most cases <3 cm. The number of cryoprobes used for cryoablation ranged from 1 to 6, and only 10 series described the use of 17-gauge (1.47 mm) third-generation needles. Overall, more than 55% of all ablated lesions were pathologically confirmed RCC. Mean follow-up ranged from 9 to 93 months. Only 7 series presented a long-term follow-up of more than 36 months. Most studies were limited by a relatively short follow-up. At least four urologic groups reported intermediate- and long-term outcomes. Persistence rates ranged from 0% to 17% and recurrence rates ranged from 0% to 14%. Overall complication rates ranged from 0% to 40%. Retrospective observational data and a few prospective series on LCA of SRMs show acceptable oncological 3- to 5-year outcomes with a low recurrence rate. It has proven to be a safe procedure with an overall low complication rate. It is mainly indicated for SRMs in elderly patients affected by co-morbidity and high surgical risk bearing tumours in the anterior valve of the kidney or in contact with the ureter or neighbouring organs.
- 10 May 2012
- Published by Wiley in BJU International
- Vol. 110 (8b) , E415-E420
Differentiation between normal renal tissue and renal tumours using functional optical coherence tomography: a phase I in vivo human study
What's known on the subject? and What does the study add? Optical Coherence Tomography (OCT) was developed in the early 1990s for ophthalmological application and is currently widely accepted in ophthalmology for retinal imaging purposes. In kidneys, the first experiments were performed on transplant kidneys to investigate the ability of OCT to assess ischaemic damage of kidneys. An ex vivo pilot study on the ability of OCT to differentiate normal renal tissue from malignant renal tissue, showed positive results and here we present the results of the first in vivo experiment. The study shows for the first time that in vivo OCT is feasible and safe to perform in humans and that a significant different attenuation coefficient (as a quantitative measurement of the OCT images) is found between normal renal tissue and malignant renal tumours with a clear trend towards significance in the difference between benign and malignant renal tumours in a small pilot study. This suggests potential use of OCT in different clinical settings for diagnostic purposes in the course of renal tumours, and justifies further research. OBJECTIVE: To determine the ability of optical coherence tomography (OCT) in differentiating human renal tumours in an in‐vivo setting by assessing differences in attenuation coefficient (µ OCT ; mm – ) as a quantitative measurement. METHODS: Consecutive patients undergoing nephrectomy (partial/radical) or cryoablation for an enhancing solid renal tumour were included in our centre between October 2010 and May 2011. In vivo OCT images were obtained from renal tumour and normal parenchyma during surgery. Ex vivo OCT images of internal (subcapsular) tissue were obtained after longitudinal dissection of the extirpated specimen. Attenuation coefficients of the OCT images were determined off‐line and compared between normal renal parenchyma and renal tumours (grouped per tissue type and per individual patient); and between OCT images recorded from tissue surface vs internal (subcapsular) tissue. RESULTS: In vivo OCT was performed in 16 cases (11 renal cell carcinoma, three benign tumours, one non‐diagnostic biopsy and one not‐accessible tumour). Median attenuation coefficient of normal renal parenchyma was 5.0 mm −1 vs 8.2 mm −1 for tumour tissue ( P < 0.001) with normal parenchyma differing significantly from malignant tumour (9.2 mm −1 , P < 0.001) and non‐significantly from benign tumour (7.0 mm −1 , P = 0.050). The attenuation coefficient of benign tumours did not differ significantly from that of malignant tumours (7.0 vs 9.2 mm −1 , P = 0.139). Using patients as their own control, attenuation coefficients of normal renal parenchyma differed significantly from malignant tumour ( P < 0.001) and non‐significantly from benign tumour ( P = 0.109). Assessed in 10 patients, there was no significant difference between attenuation coefficients of tumour surface and internal tumour (8.5 vs 9.7 mm −1 respectively, P = 0.260). CONCLUSIONS: In this first in vivo study on OCT for differentiation of renal tumours in humans the attenuation coefficients (as a quantitative assessment) differed significantly between normal renal parenchyma and malignant tumour. Tumour surface and internal tumour did not differ significantly, suggesting that a superficial OCT attenuation coefficient reliably assesses tissue composition inside the tumour. These results justify further research on OCT for various clinical applications in the diagnosis of renal tumours.
- 10 May 2012
- Published by Wiley in BJU International
- Vol. 110 (8b) , E415-E420
Differentiation between normal renal tissue and renal tumours using functional optical coherence tomography: a phase I in vivo human study
What's known on the subject? and What does the study add? Optical Coherence Tomography (OCT) was developed in the early 1990s for ophthalmological application and is currently widely accepted in ophthalmology for retinal imaging purposes. In kidneys, the first experiments were performed on transplant kidneys to investigate the ability of OCT to assess ischaemic damage of kidneys. An ex vivo pilot study on the ability of OCT to differentiate normal renal tissue from malignant renal tissue, showed positive results and here we present the results of the first in vivo experiment. The study shows for the first time that in vivo OCT is feasible and safe to perform in humans and that a significant different attenuation coefficient (as a quantitative measurement of the OCT images) is found between normal renal tissue and malignant renal tumours with a clear trend towards significance in the difference between benign and malignant renal tumours in a small pilot study. This suggests potential use of OCT in different clinical settings for diagnostic purposes in the course of renal tumours, and justifies further research. OBJECTIVE: To determine the ability of optical coherence tomography (OCT) in differentiating human renal tumours in an in‐vivo setting by assessing differences in attenuation coefficient (µ OCT ; mm – ) as a quantitative measurement. METHODS: Consecutive patients undergoing nephrectomy (partial/radical) or cryoablation for an enhancing solid renal tumour were included in our centre between October 2010 and May 2011. In vivo OCT images were obtained from renal tumour and normal parenchyma during surgery. Ex vivo OCT images of internal (subcapsular) tissue were obtained after longitudinal dissection of the extirpated specimen. Attenuation coefficients of the OCT images were determined off‐line and compared between normal renal parenchyma and renal tumours (grouped per tissue type and per individual patient); and between OCT images recorded from tissue surface vs internal (subcapsular) tissue. RESULTS: In vivo OCT was performed in 16 cases (11 renal cell carcinoma, three benign tumours, one non‐diagnostic biopsy and one not‐accessible tumour). Median attenuation coefficient of normal renal parenchyma was 5.0 mm −1 vs 8.2 mm −1 for tumour tissue ( P < 0.001) with normal parenchyma differing significantly from malignant tumour (9.2 mm −1 , P < 0.001) and non‐significantly from benign tumour (7.0 mm −1 , P = 0.050). The attenuation coefficient of benign tumours did not differ significantly from that of malignant tumours (7.0 vs 9.2 mm −1 , P = 0.139). Using patients as their own control, attenuation coefficients of normal renal parenchyma differed significantly from malignant tumour ( P < 0.001) and non‐significantly from benign tumour ( P = 0.109). Assessed in 10 patients, there was no significant difference between attenuation coefficients of tumour surface and internal tumour (8.5 vs 9.7 mm −1 respectively, P = 0.260). CONCLUSIONS: In this first in vivo study on OCT for differentiation of renal tumours in humans the attenuation coefficients (as a quantitative assessment) differed significantly between normal renal parenchyma and malignant tumour. Tumour surface and internal tumour did not differ significantly, suggesting that a superficial OCT attenuation coefficient reliably assesses tissue composition inside the tumour. These results justify further research on OCT for various clinical applications in the diagnosis of renal tumours.
- 29 February 2012
- Published by Elsevier in European Urology Supplements
- Vol. 11 (1) , e930-e930a
930 A prospective in-vivo phase-I study on optical coherence tomography for renal tumor differentiation
- 29 February 2012
- Published by Elsevier in European Urology Supplements
- Vol. 11 (1) , e930-e930a
930 A prospective in-vivo phase-I study on optical coherence tomography for renal tumor differentiation
- 1 September 2011
- Vol. 63 (3) , 213-25
New optical diagnostic tools in renal cell cancer.
In modern medicine the profound use of abdominal imaging has led to a dramatic change of presentation of renal tumors. Smaller tumors and therefore more benign masses are being discovered, and as systemic use of renal mass biopsies is not recommended by the general guidelines, an appropriate tool to assess the biology of renal tumors is highly desirable. Apart from new developments of currently applied diagnostic modalities, several research groups focus on the potential of optical diagnostic techniques to contribute to the diagnostic process of renal tumors. They use the interaction of light with biological tissue to gather information on the optical properties of a tissue sample and therefore providing information on the histological composition of this tissue in a non-invasive manner and in real-time. In this review we provide an overview of novel diagnostic techniques starting with the future of conventional diagnostics like Contrast-enhanced ultrasonography (CEUS) and positron emission tomography-computed tomography (PET-CT) followed by optical technologies that are potentially employed in the nearby future to improve the diagnostic process of renal tumors with a focus on optical diagnostic techniques.
- 1 September 2011
- Vol. 63 (3) , 213-25
New optical diagnostic tools in renal cell cancer.
In modern medicine the profound use of abdominal imaging has led to a dramatic change of presentation of renal tumors. Smaller tumors and therefore more benign masses are being discovered, and as systemic use of renal mass biopsies is not recommended by the general guidelines, an appropriate tool to assess the biology of renal tumors is highly desirable. Apart from new developments of currently applied diagnostic modalities, several research groups focus on the potential of optical diagnostic techniques to contribute to the diagnostic process of renal tumors. They use the interaction of light with biological tissue to gather information on the optical properties of a tissue sample and therefore providing information on the histological composition of this tissue in a non-invasive manner and in real-time. In this review we provide an overview of novel diagnostic techniques starting with the future of conventional diagnostics like Contrast-enhanced ultrasonography (CEUS) and positron emission tomography-computed tomography (PET-CT) followed by optical technologies that are potentially employed in the nearby future to improve the diagnostic process of renal tumors with a focus on optical diagnostic techniques.
- 1 September 2011
- Published by SAGE Publications in Journal of Endourology
- Vol. 25 (9) , 1463-1468
Are There Parameters that Predict a Nondiagnostic Biopsy Outcome Taken During Laparoscopic-Assisted Cryoablation of Small Renal Tumors?
Background and Purpose: The histopathologic diagnosis of a small renal mass (SRM) that is managed with cryoablation relies on preoperative or intraoperative biopsies. Because a considerable number of these SRMs are benign, accurate diagnosis has prognostic and follow-up implications. The main problem in SRMs is the high rate of nondiagnostic biopsies. Our purpose was to assess whether certain tumor and biopsy characteristics are correlated with a diagnostic biopsy outcome. Patients and Methods: One hundred tumors that were smaller than 4.5 cm in 94 patients were managed with laparoscopic cryoablation. After dissection of the perirenal fat and identification of the tumor by intra-abdominal ultrasonography, one or more biopsies were obtained before freezing. Using the Student t/Mann Whitney U test, the following parameters were evaluated for predicting biopsy outcome: Tumor size, location, and exophytic part of the tumor, size of the biopsy needle, the number of biopsies taken, and presence of nonenhancing areas compatible with necrosis inside the tumors. Correlations among parameters were assessed using a Spearman correlation or Kruskal-Wallis test. Results: Twenty-two (22%) biopsies were nondiagnostic and consisted of normal kidney tissue, connective tissue, fat, fibrosis, necrosis, and/or blood. There were no significant differences in parameters between the diagnostic and nondiagnostic group. There was a positive correlation between tumor size and number of biopsies (P=0.029) and between the presence of nonenhancing areas and both size (PPConclusion: No statistical significant correlation was found between biopsy outcome and tumor or biopsy characteristics. More biopsies were taken in larger tumors, and larger tumors contained more nonenhancing areas that were suspect for necrosis.
- 1 September 2011
- Published by SAGE Publications in Journal of Endourology
- Vol. 25 (9) , 1463-1468
Are There Parameters that Predict a Nondiagnostic Biopsy Outcome Taken During Laparoscopic-Assisted Cryoablation of Small Renal Tumors?
Background and Purpose: The histopathologic diagnosis of a small renal mass (SRM) that is managed with cryoablation relies on preoperative or intraoperative biopsies. Because a considerable number of these SRMs are benign, accurate diagnosis has prognostic and follow-up implications. The main problem in SRMs is the high rate of nondiagnostic biopsies. Our purpose was to assess whether certain tumor and biopsy characteristics are correlated with a diagnostic biopsy outcome. Patients and Methods: One hundred tumors that were smaller than 4.5 cm in 94 patients were managed with laparoscopic cryoablation. After dissection of the perirenal fat and identification of the tumor by intra-abdominal ultrasonography, one or more biopsies were obtained before freezing. Using the Student t/Mann Whitney U test, the following parameters were evaluated for predicting biopsy outcome: Tumor size, location, and exophytic part of the tumor, size of the biopsy needle, the number of biopsies taken, and presence of nonenhancing areas compatible with necrosis inside the tumors. Correlations among parameters were assessed using a Spearman correlation or Kruskal-Wallis test. Results: Twenty-two (22%) biopsies were nondiagnostic and consisted of normal kidney tissue, connective tissue, fat, fibrosis, necrosis, and/or blood. There were no significant differences in parameters between the diagnostic and nondiagnostic group. There was a positive correlation between tumor size and number of biopsies (P=0.029) and between the presence of nonenhancing areas and both size (PPConclusion: No statistical significant correlation was found between biopsy outcome and tumor or biopsy characteristics. More biopsies were taken in larger tumors, and larger tumors contained more nonenhancing areas that were suspect for necrosis.
- Open Access
- 28 May 2011
- Published by Springer Nature in World Journal of Urology
- Vol. 31 (4) , 823-827
What is the added value of combined core biopsy and fine needle aspiration in the diagnostic process of renal tumours?
Purpose Non-diagnostic results still hinder the routine use of core biopsy (CB) and fine needle aspiration (FNA) in the diagnostic process of renal tumours. Furthermore, substantial interobserver variability has been reported. We assessed the added value of combining the results of CB and FNA by five pathologists in the ex vivo diagnosis of renal mass. Methods Two ex vivo core biopsies were taken followed by two FNA passes from extirpated tumours. All samples were evaluated by five blinded pathologists. A consensus diagnosis of the surgical specimen was the index for comparison. For each pathologist, the number of non-diagnostic (non-conclusive or undetermined biology and failed biopsies), correct and incorrect scored cases of each technique was assessed. When a non-diagnostic CB or FNA had a correct diagnostic counterpart, this was considered as of added value. Results Of the 57 assessed tumours, 53 were malignant. CB was non-diagnostic in 4–10 cases (7–17.5%). FNA established the correct diagnosis in 1–7 of these cases. FNA was non-diagnostic in 2–6 cases (3.5–10.5%), and the counterpart CB established the correct diagnosis in 1–6 of these cases. For the 5 pathologists, accuracy of CB and FNA varied between 82.5–93% and 89.5–96.5%, respectively. Combination of both types of biopsy resulted in 55–57 correct results (accuracy 96.5–100%), i.e., an increase in accuracy of 3.5–14%. Conclusion Combining the result of CB and FNA in renal mass biopsy leads to a higher diagnostic accuracy. Recommendations on which technique used should be adapted to local expertise and logistic possibilities.
- 28 May 2011
- Published by Springer Nature in World Journal of Urology
- Vol. 31 (4) , 823-827
Open AccessWhat is the added value of combined core biopsy and fine needle aspiration in the diagnostic process of renal tumours?
Purpose Non-diagnostic results still hinder the routine use of core biopsy (CB) and fine needle aspiration (FNA) in the diagnostic process of renal tumours. Furthermore, substantial interobserver variability has been reported. We assessed the added value of combining the results of CB and FNA by five pathologists in the ex vivo diagnosis of renal mass. Methods Two ex vivo core biopsies were taken followed by two FNA passes from extirpated tumours. All samples were evaluated by five blinded pathologists. A consensus diagnosis of the surgical specimen was the index for comparison. For each pathologist, the number of non-diagnostic (non-conclusive or undetermined biology and failed biopsies), correct and incorrect scored cases of each technique was assessed. When a non-diagnostic CB or FNA had a correct diagnostic counterpart, this was considered as of added value. Results Of the 57 assessed tumours, 53 were malignant. CB was non-diagnostic in 4–10 cases (7–17.5%). FNA established the correct diagnosis in 1–7 of these cases. FNA was non-diagnostic in 2–6 cases (3.5–10.5%), and the counterpart CB established the correct diagnosis in 1–6 of these cases. For the 5 pathologists, accuracy of CB and FNA varied between 82.5–93% and 89.5–96.5%, respectively. Combination of both types of biopsy resulted in 55–57 correct results (accuracy 96.5–100%), i.e., an increase in accuracy of 3.5–14%. Conclusion Combining the result of CB and FNA in renal mass biopsy leads to a higher diagnostic accuracy. Recommendations on which technique used should be adapted to local expertise and logistic possibilities.
- 1 February 2011
- Published by SAGE Publications in Journal of Endourology
- Vol. 25 (2) , 311-315
Advanced Diagnostics in Renal Mass Using Optical Coherence Tomography: A Preliminary Report
Objective: To avoid unnecessary surgical treatment of small renal masses (≤4 cm), a more accurate diagnostic method would be desirable since radiological differentiation between malignant and benign is difficult and nondiagnostic biopsies account from 9% to 37%. Optical coherence tomography (OCT) measures backscattered light versus depth, with an attenuation coefficient (μt) that may vary among different histological types. We hypothesize that quantitative measurements of μt using OCT can differentiate between normal renal parenchyma and renal cell carcinoma (RCC). Materials and Methods: Both normal and tumor renal tissues (RCC) were harvested after partial or radical nephrectomy. Analysis of μt was based on difference of (1) μt between normal and tumor tissue across all patients and (2) μt between normal and tumor tissue within individual patients. Results: Tissue samples of 18 patients were measured, of which 4 were excluded (urothelial carcinoma, oncocytoma, and benign lesion without normal tissue available). Of the remaining 14 patients, 8 contributed with both normal and RCC tissue and 6 with only normal or RCC tissue. Independent observation showed a significant difference between the median μt of normal renal tissue (4.95 mm−1) and the median μt of RCC (8.86 mm−1). No statistically significant difference was found when comparing the difference in μt between normal renal parenchyma and RCC within individual patients. Conclusion: There is a significant difference in μt between normal and RCC tissue across all patients. These results overpower the lack of significant difference within individuals, encouraging further research and suggesting a possible role for OCT in the diagnostic work-up of renal masses.
- 1 February 2011
- Published by SAGE Publications in Journal of Endourology
- Vol. 25 (2) , 311-315
Advanced Diagnostics in Renal Mass Using Optical Coherence Tomography: A Preliminary Report
Objective: To avoid unnecessary surgical treatment of small renal masses (≤4 cm), a more accurate diagnostic method would be desirable since radiological differentiation between malignant and benign is difficult and nondiagnostic biopsies account from 9% to 37%. Optical coherence tomography (OCT) measures backscattered light versus depth, with an attenuation coefficient (μt) that may vary among different histological types. We hypothesize that quantitative measurements of μt using OCT can differentiate between normal renal parenchyma and renal cell carcinoma (RCC). Materials and Methods: Both normal and tumor renal tissues (RCC) were harvested after partial or radical nephrectomy. Analysis of μt was based on difference of (1) μt between normal and tumor tissue across all patients and (2) μt between normal and tumor tissue within individual patients. Results: Tissue samples of 18 patients were measured, of which 4 were excluded (urothelial carcinoma, oncocytoma, and benign lesion without normal tissue available). Of the remaining 14 patients, 8 contributed with both normal and RCC tissue and 6 with only normal or RCC tissue. Independent observation showed a significant difference between the median μt of normal renal tissue (4.95 mm−1) and the median μt of RCC (8.86 mm−1). No statistically significant difference was found when comparing the difference in μt between normal renal parenchyma and RCC within individual patients. Conclusion: There is a significant difference in μt between normal and RCC tissue across all patients. These results overpower the lack of significant difference within individuals, encouraging further research and suggesting a possible role for OCT in the diagnostic work-up of renal masses.